Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01447225 · ClinicalTrials.gov registry record · Phase 1
Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Merrimack Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
NCT01447225 is a Phase 1 study that has completed, run by Merrimack Pharmaceuticals. The registered enrollment target is 43 participants.
The verdict
NCT01447225, a Phase 1 study, has completed, sponsored by Merrimack Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
To evaluate the safety and tolerability of escalating doses of MM-121 + certain anticancer therapies
Interventions
- DRUG Carboplatin
- DRUG Pemetrexed
- DRUG Gemcitabine
- DRUG Cabazitaxel
- DRUG MM-121
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2011-10 |
| Est. Completion | 2014-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01447225
The ClinicalTrials.gov registry entry for NCT01447225 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merrimack Pharmaceuticals, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT01447225 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01447225 about?
NCT01447225 is a clinical study titled "Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors". To evaluate the safety and tolerability of escalating doses of MM-121 + certain anticancer therapies
What is the current status of trial NCT01447225?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2011-10. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01447225?
The interventions under investigation include: Carboplatin (DRUG), Pemetrexed (DRUG), Gemcitabine (DRUG), Cabazitaxel (DRUG), MM-121 (DRUG).
Who is sponsoring clinical trial NCT01447225?
This trial is sponsored by Merrimack Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.